New Horizon Health

New Horizon Health EBITDA

Delisted·Feb 9, 2026

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of New Horizon Health (6606.HK) as of Oct 23, 2026 is -158.13 M CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -3.54 B CNY — a change of -95.53% (higher).

EBITDA

-158.13 MCNY

YoY

-95.53%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of New Horizon Health is 2022 -158.13 M CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of New Horizon Health was 2021 -3.54 B CNY. It decreases by -95.53% higher compared to the previous year.

The New Horizon Health EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-83.55 M CNY
Jan 1, 2019
-105.22 M CNY
Jan 1, 2020
-887.33 M CNY
Jan 1, 2021
-3.54 B CNY
Jan 1, 2022
-158.13 M CNY
The New Horizon Health EBITDA history
YEAREBITDAYoY
-158.13 MCNY-95.53%
-3.54 BCNY+298.65%
-887.33 MCNY+743.27%
-105.22 MCNY+25.95%
-83.55 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

New Horizon Health Stock analysis

What does New Horizon Health do? New Horizon Health Ltd. generates revenue through the distribution of its ColoClear and Pupu tube products via its own network, contracted sales organisations (CSOs), and e-platforms managed by healthcare clinics. The company also develops Youyou Tube, a stool-based self-checking gastric cancer screening test, and CerviClear, a non-invasive urine cervical cancer home screening test, which are currently under development. Its primary customers include healthcare clinics and end-users seeking non-invasive cancer screening solutions. The firm's product portfolio focuses on innovative medical screening tools, targeting the growing demand for accessible and user-friendly health diagnostics. By leveraging its internal sales channels and partnerships with CSOs, New Horizon Health Ltd. ensures broad market reach for its products. The company's development of Youyou Tube and CerviClear reflects its strategic emphasis on expanding into high-need areas of cancer prevention and early detection. Revenue streams are derived from the sale of ColoClear and Pupu tube products, with future potential from the commercialization of Youyou Tube and CerviClear once development is complete. The company's business model relies on direct and indirect sales channels to healthcare providers and consumers, positioning it within the medical diagnostics sector. New Horizon Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about New Horizon Health stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of New Horizon Health is -158.13 M CNY in 2022.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of New Horizon Health changed from -3.54 B CNY to -158.13 M CNY, representing a -95.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) New Horizon Health since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s New Horizon Health historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — New Horizon Health

All Key Metrics — New Horizon Health